Skip to main content

Table 2 Results of Kaplan–Meier and ROC analysis based on different regrouping methods

From: A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Regrouping factors Group Sample size Kaplan–Meier, P value AUC 95% CI of AUC
Age at diagnosis ≤ 50 127 1.32E−02 0.680 0.56–0.80
51–60 178 9.40E−05 0.774 0.69–0.86
> 60 246 1.17E−04 0.720 0.65–0.79
FIGO stage I and II 42 6.76E−02 0.778 0.59–0.96
III and IV 505 1.03E−09 0.735 0.69–0.79
Histologic grade G2 69 2.91E−02 0.696 0.53–0.86
G3 478 3.26E−09 0.740 0.69–0.79
Anatomic subdivision Unilateral 140 4.27E−04 0.753 0.66–0.85
Bilateral 383 4.73E−07 0.727 0.67–0.79
Tumor residual disease (mm) No macroscopic disease 116 1.17E−03 0.795 0.67–0.92
1–10 255 1.16E−03 0.665 0.59–0.76
> 10 138 5.18E−05 0.770 0.68–0.86